CD274 and urinary bladder carcinoma: Combining the NetBio expression levels and TMB improved the prediction of the overall survival in bladder cancer patients treated with atezolizumab, which is a PD-L1 inhibitor (Fig. 7b, c and Supplementary Fig. 21).